ColdZyme® Mouth Spray (ColdZyme) is intended to reduce the probability of catching a cold and/or can help shorten the duration of a cold, if used at an early stage of the infection, by forming a barrier on the pharyngeal mucous membrane. The user experience of ColdZyme on naturally occurring common cold infections was evaluated in competitive athletes training professionally or on an amateur level. Thirteen athletes completed weekly electronic surveys on occurrence of common colds, cold severity and user experience over the course of 3 months. The 13 participants reported in total 15 cold incidents with an average duration of 7.4 days. The average cold severity was 31.2 on a visual-analogue scale (VAS) ranging from 0 (mildest possible cold) to 100 (worst possible cold). The overall user satisfaction with ColdZyme was high. 81% of the reported colds were experienced to be milder and/or shorter than usual. None of the participants reported "No effect". Out of the participants who reported absence of a cold in the previous week, 69% reported a positive answer to the question if ColdZyme had prevented them from catching a cold in the previous week. Conclusion: The present study evaluated prevention and alleviation of naturally occurring common cold in athletes, and demonstrated that ColdZyme may be an easy and practical way for competitive athletes to prevent or reduce infections of the common cold virus and corresponding unwanted absence from training and competition. Due to the lack of a comparator group, a placebo effect cannot be excluded.
BackgroundPrimary immunodeficiencies include a variety of disorders that render patients more susceptible to infections. If left untreated, these infections may be fatal. Patients with primary antibody deficiencies are therefore given prophylactic immunoglobulin G replacement therapy. ColdZyme® Mouth Spray is a medical device intended to reduce the probability of catching a cold and/or can help shorten the duration of a cold, if used at an early stage of the infection, by forming a thin protective barrier on the pharyngeal mucous membrane. This is the first report of this kind in the literature.Case presentationThe parents of a 12-year-old white boy diagnosed as having common variable immunodeficiency voluntarily started to let their son use ColdZyme® Mouth Spray to reduce common cold infections if possible. Prior to using ColdZyme® Mouth Spray, he had recurrent microbial infections of his ears, sinuses, nose, bronchi, and lungs. He also frequently exhibited continuous rhinorrhea, fungal growth in his oral cavity, and gingivitis with wounds in his gums. As a consequence, his and his family’s health-related quality of life was severely compromised. He commenced a twice-daily treatment (morning and evening) with ColdZyme® Mouth Spray; the weekly administration of immunoglobulin G (Hizentra®) for replacement therapy was continued throughout this period. Data were retrieved by using a daily diary about infections and symptoms. His guardians had recorded infection symptoms since he was diagnosed as having common variable immunodeficiency 10 years earlier to follow the effect of the immunoglobulin G treatment. Shortly after commencement of ColdZyme® Mouth Spray treatment, he experienced a marked improvement in symptoms and health-related quality of life. His continuous rhinorrhea disappeared, breathing through his nose was easier, oral fungal infection decreased, and wounds in his gum tissue healed for the first time in several years.ConclusionsWe observed that when ColdZyme® Mouth Spray was used to reduce common cold viral infection in a patient with common variable immunodeficiency on immunoglobulin G replacement therapy, secondary microbial and fungal infections in his oral cavity and oropharynx were also reduced. A controlled study is warranted to confirm the observed results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.